Drug Profile
Research programme: CNS therapeutics - Aphios Pharma
Alternative Names: APH 1501Latest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Aphios Pharma
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 25 Nov 2021 Discontinued for CNS disorders in USA (unspecified route) in November 2021 (Aphios Corporation pipeline, November 2021)
- 28 Mar 2021 No recent reports of development identified for research development in CNS-disorders in USA
- 30 Jan 2019 Aphios plans a phase I trial for Opioid abuse in January 2020 (NCT03813095)